Cargando…
Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
BACKGROUND: Two anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (-TKIs) have been approved for the treatment of patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer (NSCLC). Severe hepatotoxicity has been observed in several clinical studies. We aim to assess t...
Autores principales: | Liu, Bing, Yuan, Maoxi, Sun, Yi, Cheng, Ziming, Zhang, Zaiyong, Hou, Shizheng, Wang, Xiangdong, Liu, Jingfeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823621/ https://www.ncbi.nlm.nih.gov/pubmed/29507704 http://dx.doi.org/10.18632/oncotarget.23840 |
Ejemplares similares
-
Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis
por: Tantai, Xin-Xing, et al.
Publicado: (2019) -
Risk of venous and arterial thromboembolic events associated with tyrosine kinase inhibitors in advanced thyroid cancer: a meta-analysis and systematic review
por: Bai, Yang, et al.
Publicado: (2018) -
Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis
por: Weng, Chenghua, et al.
Publicado: (2021) -
Systematic Review and Meta-Analysis of Multitargeted Tyrosine Kinase Inhibitors in Patients With Intractable Metastatic Colorectal Cancer
por: Gao, Zhenzhen, et al.
Publicado: (2020) -
Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer
por: Costa, Rubens Barros, et al.
Publicado: (2018)